CytomX Therapeutics (CTMX) Total Liabilities (2014 - 2026)

CytomX Therapeutics' Total Liabilities history runs 13 years deep, the most recent figure standing at $39.4 million for Q1 2026.

• Quarterly Total Liabilities fell 46.34% year-over-year to $39.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $39.4 million (down 46.34% YoY) and the FY2025 annual result came in at $52.6 million, down 56.56% from the prior year.
• Total Liabilities was $39.4 million for Q1 2026 at CytomX Therapeutics, down from $52.6 million in the prior quarter.
• Across five years, Total Liabilities topped out at $346.6 million in Q4 2022 and bottomed at $39.4 million in Q1 2026.
• A 5-year average of $199.6 million and a median of $216.4 million in 2024 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2022 — Total Liabilities gained 1.99% — and 2025, when it tumbled 71.04%.
• CytomX Therapeutics' Total Liabilities stood at $346.6 million in 2022, then fell by 28.1% to $249.2 million in 2023, then sank by 51.46% to $121.0 million in 2024, then tumbled by 56.56% to $52.6 million in 2025, then decreased by 25.01% to $39.4 million in 2026.
• Business Quant data shows CTMX's Total Liabilities at $39.4 million in Q1 2026, $52.6 million in Q4 2025, and $50.9 million in Q3 2025.